The estimated Net Worth of Roy T Eddleman is at least $71.3 Million dollars as of 9 August 2018. Roy Eddleman owns over 116,073 units of Repligen stock worth over $53,058,000 and over the last 7 years Roy sold RGEN stock worth over $18,280,242.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Roy Eddleman RGEN stock SEC Form 4 insiders trading
Roy has made over 4 trades of the Repligen stock since 2018, according to the Form 4 filled with the SEC. Most recently Roy sold 116,073 units of RGEN stock worth $5,760,703 on 9 August 2018.
The largest trade Roy's ever made was selling 120,000 units of Repligen stock on 8 May 2018 worth over $4,874,400. On average, Roy trades about 58,407 units every 13 days since 2017. As of 9 August 2018 Roy still owns at least 370,000 units of Repligen stock.
You can see the complete history of Roy Eddleman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Roy Eddleman's mailing address?
Roy's mailing address filed with the SEC is 1801 Century Park E, Los Angeles, CA 90067, USA.
Insiders trading at Repligen
Over the last 22 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir, and Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.
What does Repligen do?
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
What does Repligen's logo look like?
Complete history of Roy Eddleman stock trades at Repligen
Repligen executives and stock owners
Repligen executives and other stock owners filed with the SEC include:
-
Anthony Hunt,
President, Chief Executive Officer, Director -
Jon Snodgres,
Chief Financial Officer -
Ralf Kuriyel,
Senior Vice President - Research and Development -
Anthony J. Hunt,
CEO, Pres & Director -
Jon K. Snodgres,
Chief Financial Officer -
Ralf Kuriyel,
Sr. VP of R&D -
Karen Dawes,
Independent Chairperson of the Board -
Glenn Muir,
Independent Director -
Thomas Ryan,
Independent Director -
Nicolas Barthelemy,
Independent Director -
Rohin Mhatre,
Independent Director -
Carrie Eglinton,
Director -
James Slaughter,
Chief HR Officer -
James R. Bylund,
Chief Operating Officer -
Christine Gebski,
Sr. VP of Filtration & Chromatography -
Ken Elmer,
Global Head of HR -
Rachel Goodrich,
VP of Marketing -
Stephen Tingley,
VP of Global Sales -
Squire Servance,
Sr. VP, Gen. Counsel & Corp. Sec. -
Sondra S. Newman,
Global Head of Investor Relations -
Jim Bylund,
Sr. VP of Operations & Information Technology -
Jason K Garland,
CFO -
Glenn L Md Cooper,
Director -
James R Rusche,
Senior Vice President -
John Cox,
Director -
Howard Benjamin,
-
Roy T Eddleman,
10% owner -
Christine Gebski,
See Remarks -
G William Miller,
Director -
Timothy Scott Harris,
-
Barbara Burnim Day,
Vice President -
Daniel W Muehl,
CFO -
Partners L P/Ilbiotechnolog...,
-
Alfred Lewis Goldberg,
Director -
Walter C Herlihy,
PRESIDENT, CEO -
Michael A Griffith,
Director -
Daniel P Witt,
Vice President -
Jonathan I Lieber,
CFO -
Earl Webb Henry,
Director -
William J Kelly,
Vice President -
Alexander Rich,
Director -
Partners L P/Ilbiotechnolog...,
-
Hal Landy,
Vice President -
Paul Schimmel,
Director -
Laura Whitehouse,
Vice President -
Robert J Hennessey,
Director -
Margaret Pax,
-
Konstantin Konstantinov,
-
Martin D Madaus,
-
James Bylund,
Chief Operating Officer -
Olivier Loeillot,
Chief Executive Officer